Liver Resection for Neuroendocrine Tumor Liver Metastases Within Milan Criteria for Liver Transplantation.
Liver surgery
Liver transplant
Neuroendocrine liver metastasis
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
01
06
2018
accepted:
11
09
2018
pubmed:
23
9
2018
medline:
15
2
2020
entrez:
23
9
2018
Statut:
ppublish
Résumé
The role of liver transplant (LT) for neuroendocrine liver metastasis (NELM) has not been completely defined. While international guidelines included LT as a potential treatment for highly selected patients with advanced NELM, recently, LT has been proposed as an alternative curative treatment for NELM for patients meeting restrictive criteria (Milan criteria). Using a multi-institutional cohort of patients undergoing liver resection for NELM, the long-term outcomes of patients meeting Milan criteria (resected NET drained by the portal system, stable disease/response to therapies for at least 6 months, metastatic diffusion to < 50% of the total liver volume, a confirmed histology of low-grade, and ≤ 60 years) were investigated. Among the 238 patients included in the study, 28 (12%) patients met the Milan criteria for LT with a 5-year OS of 83%. Furthermore, among patients meeting Milan criteria, subsets of patients with favorable clinic-pathological characteristics had 5-year OS rates greater than 90% including G1 patients (5-year OS, 92%), patients undergoing minor liver resection (5-year OS, 94%), patients with low number of NELM (1-2 NELM), and small tumor size (< 3 cm) (for both groups of patients, 5-year OS, 100%). In our series, only 12% of patients met Milan criteria, and the 5-year OS after liver resection for this small selected group of patients was comparable with that reported in the literature for patients undergoing LT for NELM within Milan criteria. While LT might be the optimal treatment for patients with unresectable NELM, surgical resection should be the first option for patients with resectable NELM.
Sections du résumé
BACKGROUND
The role of liver transplant (LT) for neuroendocrine liver metastasis (NELM) has not been completely defined. While international guidelines included LT as a potential treatment for highly selected patients with advanced NELM, recently, LT has been proposed as an alternative curative treatment for NELM for patients meeting restrictive criteria (Milan criteria).
METHODS
Using a multi-institutional cohort of patients undergoing liver resection for NELM, the long-term outcomes of patients meeting Milan criteria (resected NET drained by the portal system, stable disease/response to therapies for at least 6 months, metastatic diffusion to < 50% of the total liver volume, a confirmed histology of low-grade, and ≤ 60 years) were investigated.
RESULTS
Among the 238 patients included in the study, 28 (12%) patients met the Milan criteria for LT with a 5-year OS of 83%. Furthermore, among patients meeting Milan criteria, subsets of patients with favorable clinic-pathological characteristics had 5-year OS rates greater than 90% including G1 patients (5-year OS, 92%), patients undergoing minor liver resection (5-year OS, 94%), patients with low number of NELM (1-2 NELM), and small tumor size (< 3 cm) (for both groups of patients, 5-year OS, 100%).
CONCLUSIONS
In our series, only 12% of patients met Milan criteria, and the 5-year OS after liver resection for this small selected group of patients was comparable with that reported in the literature for patients undergoing LT for NELM within Milan criteria. While LT might be the optimal treatment for patients with unresectable NELM, surgical resection should be the first option for patients with resectable NELM.
Identifiants
pubmed: 30242647
doi: 10.1007/s11605-018-3973-9
pii: 10.1007/s11605-018-3973-9
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
93-100Références
Lancet. 2016 Mar 5;387(10022):968-977
pubmed: 26703889
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007060
pubmed: 19370671
World J Gastroenterol. 2014 Oct 21;20(39):14348-58
pubmed: 25339822
Neuroendocrinology. 2012;95(2):157-76
pubmed: 22262022
J Gastrointest Surg. 2017 Jan;21(1):41-48
pubmed: 27503330
Am J Transplant. 2016 Oct;16(10):2892-2902
pubmed: 27134017
Ann Surg. 2013 May;257(5):807-15
pubmed: 23532105
J Hepatol. 2007 Oct;47(4):460-6
pubmed: 17697723
Surgery. 2001 Oct;130(4):677-82; discussion 682-5
pubmed: 11602899
Curr Oncol Rep. 2017 Feb;19(2):9
pubmed: 28220446
J Am Coll Surg. 2000 Apr;190(4):432-45
pubmed: 10757381
Pancreas. 2010 Aug;39(6):707-12
pubmed: 20664470
N Engl J Med. 2011 Feb 10;364(6):501-13
pubmed: 21306237
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Ann Surg Oncol. 2006 Apr;13(4):572-81
pubmed: 16511671
HPB (Oxford). 2002;4(2):99; author reply 99-100
pubmed: 18332933
HPB (Oxford). 2015 Jan;17(1):23-8
pubmed: 24992381
J Gastrointest Surg. 2017 Dec;21(12):2039-2047
pubmed: 28744737
Neuroendocrinology. 2016;103(2):172-85
pubmed: 26731013
Hematol Oncol Clin North Am. 2016 Feb;30(1):179-91
pubmed: 26614376
Gland Surg. 2018 Feb;7(1):28-35
pubmed: 29629317
Endocrinol Metab Clin North Am. 2011 Mar;40(1):1-18, vii
pubmed: 21349409
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
World J Gastroenterol. 2014 May 14;20(18):5345-52
pubmed: 24833864
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Neuroendocrinology. 2008;87(1):47-62
pubmed: 18097131
Arch Surg. 2011 Aug;146(8):953-8
pubmed: 21844436
Transplant Proc. 2001 Feb-Mar;33(1-2):1537-9
pubmed: 11267413
Ann Oncol. 2010 Sep;21(9):1794-803
pubmed: 20139156
J Gastroenterol. 2015 Jan;50(1):58-64
pubmed: 24499825
N Engl J Med. 2014 Jul 17;371(3):224-33
pubmed: 25014687
Cancer. 2015 Feb 15;121(4):589-97
pubmed: 25312765
Surg Oncol. 2012 Sep;21(3):e131-41
pubmed: 22658833
Br J Surg. 2009 Feb;96(2):175-84
pubmed: 19160361
Ann Surg Oncol. 2011 Dec;18(13):3657-65
pubmed: 21681380
J Clin Oncol. 2009 Oct 1;27(28):4656-63
pubmed: 19704057